Last reviewed · How we verify
Fluarix and adjuvanted influenza vaccine — Competitive Intelligence Brief
phase 2
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
Fluarix and adjuvanted influenza vaccine (Fluarix and adjuvanted influenza vaccine) — GlaxoSmithKline. Fluarix and adjuvanted influenza vaccine works by stimulating the body's immune system to produce antibodies against the influenza virus.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fluarix and adjuvanted influenza vaccine TARGET | Fluarix and adjuvanted influenza vaccine | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fluarix and adjuvanted influenza vaccine CI watch — RSS
- Fluarix and adjuvanted influenza vaccine CI watch — Atom
- Fluarix and adjuvanted influenza vaccine CI watch — JSON
- Fluarix and adjuvanted influenza vaccine alone — RSS
Cite this brief
Drug Landscape (2026). Fluarix and adjuvanted influenza vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/fluarix-and-adjuvanted-influenza-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab